All In Biotech

Drug Trial Radar · NCT07456800

PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects

A Phase 1, Double-Blind, Randomized, Crossover Study in Older Healthy Subjects to Compare the Safety, Tolerability, and Pharmacokinetics of Lyt-100 (Deupirfenidone) to Pirfenidone

Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

116

Actual

Start

Jul 12, 2021

Primary completion

Jan 1, 2022

Study completion Jan 20, 2022

Sponsor

Lead sponsor
PureTechIndustry
Sponsor type
Industry
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A three-part, randomized, double-blind study in healthy older adults to identify a dose of deupirfenidone for further clinical study.

Conditions

  • Pharmacokinetic Analysis

Interventions

  • DeupirfenidoneDrug

    Swedish orange capsule

  • Pirfenidone (PFD)Drug

    Swedish orange capsule

  • PlaceboDrug

    Swedish orange capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Cmax of BID deupirfenidone versus TID pirfenidoneTime frame: 14 days
  2. Part 2: Cmax of TID deupirfenidone versus TID pirfenidoneTime frame: 14 days
  3. Part 3: Cmax of TID deupirfenidone versus placeboTime frame: 6 days
  4. Part 1: AUC of BID deupirfenidone versus TID pirfenidoneTime frame: 14 Days
  5. Part 1: Tmax of BID deupirfenidone versus TID pirfenidoneTime frame: 14 Days
  6. Part 2: AUC of TID deupirfenidone versus TID pirfenidoneTime frame: 14 Days
  7. Part 2: Tmax of TID deupirfenidone versus TID pirfenidoneTime frame: 14 Days
  8. Part 3: AUC of TID deupirfenidone versus placeboTime frame: 6 Days
  9. Part 3: PK profile of TID deupirfenidone versus placeboTime frame: 6 Days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Network, LLC.

    Long Beach, California

  • Accel Research Sites

    Lake Mary, Florida

  • Hassman Research

    Berlin, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.